Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | MPO | P05164 | 1/20 | 0.47 |
| ▸ | LCLAT1 | Q6UWP7 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | HNF4A | P41235 | 1/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20107595 | 0.89 | KDM4E (0.50) | KDM4EPTGDR2ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL978291 | 0.84 | KDM4E (0.71) | KDM4EALDH1A1CYP1A2CYP2C9POLB | |
| SCHEMBL20521864 | 0.84 | KDM4E (0.51) | KDM4EALDH1A1CYP1A2CYP2C9MPO | |
| SCHEMBL1487907 | 0.83 | KDM4E (0.51) | KDM4EALDH1A1CYP1A2CYP2C9POLB | |
| SCHEMBL985659 | 0.83 | GAA (0.60) | KDM4EPTGDR2ALDH1A1CYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL10754121 | 0.83 | KDM4E (0.69) | KDM4EALDH1A1CYP1A2CYP2C9POLB | |
| SCHEMBL20521847 | 0.83 | KDM4E (0.54) | KDM4EALDH1A1CYP1A2CYP2C9LCLAT1 | |
| SCHEMBL3876532 | 0.80 | CYP1A2 (0.61) | KDM4EALDH1A1CYP1A2CYP2C9POLB | |
| SCHEMBL8522538 | 0.79 | ALDH1A1 (0.47) | KDM4EPTGDR2ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL945024 | 0.79 | MRGPRX4 (0.49) | KDM4EPTGDR2ALDH1A1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196197-B2 | Process for the preparation of Flecainide, its pharmaceutically acceptable salts and important intermediates thereof | APOTEX PHARMACHEM INC. | 2007-03-27 | — | — | US | claimed |
| US-20050059825-A1 | Novel process for the preparation of flecainide, its pharmaceutically acceptable salts and important intermediates thereof | APOTEX PHARMACHEM INC (CA) | 2005-03-17 | — | — | US | claimed |
| US-12630541-B2 | Compounds useful as inhibitors of ALCAT 1 | PERENNA PHARMACEUTICALS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20220089582-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1 | PERENNA PHARMACEUTICALS, INC. | 2022-03-24 | — | — | US | disclosed |
| US-11208404-B2 | Compounds useful as inhibitors of ALCAT 1 | PERENNA PHARMACEUTICALS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200109136-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1 | PERENNA PHARMACEUTICALS, INC. | 2020-04-09 | — | — | US | disclosed |
| EP-3601274-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1 | Perenna Pharmaceuticals, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| CN-110709394-A | Compounds useful as ALCAT1 inhibitors | 中美博瑞纳制药有限公司 | 2020-01-17 | — | — | CN | disclosed |
| WO-2018178304-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1 | PERENNA PHARMACEUTICALS, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
| US-7196197-B2 | Process for the preparation of Flecainide, its pharmaceutically acceptable salts and important intermediates thereof | APOTEX PHARMACHEM INC. | 2007-03-27 | — | — | US | disclosed |
| US-20050059825-A1 | Novel process for the preparation of flecainide, its pharmaceutically acceptable salts and important intermediates thereof | APOTEX PHARMACHEM INC (CA) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089582-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1 | ACAT1, ACAT2, SLC33A1 | KDM4E 3391/4885PTGDR2 4345/4885ALDH1A1 65/4885 |
| US-20050059825-A1 | Novel process for the preparation of flecainide, its pharmaceutically acceptable salts and important intermediates thereof | SCN2B, CYP2C9, HCN4 | KDM4E 1885/4885PTGDR2 812/4885ALDH1A1 738/4885 |
| US-12630541-B2 | Compounds useful as inhibitors of ALCAT 1 | LCLAT1, LPCAT1, ACAT2 | KDM4E 3151/4885PTGDR2 4035/4885ALDH1A1 511/4885 |
| US-11208404-B2 | Compounds useful as inhibitors of ALCAT 1 | ACAT1, ACAT2, SLC33A1 | KDM4E 3391/4885PTGDR2 4345/4885ALDH1A1 65/4885 |
| US-20200109136-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1 | ACAT1, ACAT2, SLC33A1 | KDM4E 3391/4885PTGDR2 4345/4885ALDH1A1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.